Detail akcie Idorsia Rg online

Business Summary: Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Idorsia Ltd revenues increased from SF52.6M to SF172.6M. Net loss decreased 81% to SF33.9M. Revenues reflect Discovering, Developing and Commercializing segment increase from SF26.4M to SF172.6M, Switzerland segment increase from SF3.9M to SF77.1M, EUCAN segment increase from SF8.3M to SF42.1M. Lower net loss reflects Discovering.